Cerebrovascular Disease

  • Michel A. Beaudry
  • Vladimir C. Hachinski
Part of the Foundations of Neurology book series (FONY, volume 1)

Abstract

The incidence of stroke deaths has declined over the past 20 years [1]. It has been argued that neurologists contributed little to this decline [2], and that modification of risk factors such as hypertension [3, 4] and other unknown factors offer a more credible explanation [5].

Keywords

Placebo Dementia Aspirin Stratification Neurol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wolf PA, Kannel WB, McGee DL (1986). Epidemiology of strokes in North America. In Barnett HJM, Stein BM, Mohr JP, Yatsu FM (eds.), Stroke. Pathophysiology, Diagnosis, and Management. New York: Churchill Livingstone, pp. 19–29.Google Scholar
  2. 2.
    Whisnant JP (1984). The decline of stroke. Stroke 15:160–167.PubMedCrossRefGoogle Scholar
  3. 3.
    Garraway WM, Whisnant JP (1987). The changing pattern of hypertension and the declining incidence of stroke. JAMA 258:214–217.PubMedCrossRefGoogle Scholar
  4. 4.
    Burke GL, Sprafka JM, Norsted SW, et al. (1988). Plateauing trends in stroke morbidity, mortality and blood pressure levels: the Minnesota Heart Survey. Am J Epidemiol 128: 917–918 (abstract).Google Scholar
  5. 5.
    Hachinski V (1984). Decreased incidence and mortality of stroke. Stroke 15:376–378.PubMedCrossRefGoogle Scholar
  6. 6.
    Mohr JP, Barnett HJM (1986). Classification of ischemic strokes. In Barnett HJM, Stein BM, Mohr JP, Yatsu FM (eds.), Stroke. Pathophysiology, Diagnosis, and Management. New York Churchill Livingstone, pp. 281–291.Google Scholar
  7. 7.
    Bogousslavsky J, Van Melle G, Regli F (1988). The Lausanne stroke registry: analysis of 1,000 consecutive patients with first stroke. Stroke 19:1083–1092.PubMedCrossRefGoogle Scholar
  8. 8.
    LaRue LJ, Alter M, Traven ND, et al. (1988). Acute stroke therapy trials: problems in patient accrual. Stroke 19:950–954.PubMedCrossRefGoogle Scholar
  9. 9.
    Wise RJS, Bernardi S, Frackowiak RSJ, et al. (1983). Serial observations on the pathophysiology of acute stroke. The transition from ischemia to infarction as reflected in regional oxygen extraction. Brain 106:197–222.PubMedCrossRefGoogle Scholar
  10. 10.
    Heyman A, Wilkinson WE, Hurwitz BJ, et al. (1984). Risk of ischemic heart disease in patients with TIA. Neurology 28:626–630.Google Scholar
  11. 11.
    Scmidt EV, Smirnov VE, Ryabova VS (1988). Results of the seven-year prospective study of stroke patients. Stroke 19:942–949.PubMedCrossRefGoogle Scholar
  12. 12.
    Bonita R, Ford MA, Stewart AW (1988). Predicting survival after stroke: a three-year follow-up. Stroke 19:669–673.PubMedCrossRefGoogle Scholar
  13. 13.
    Howard G, Toole JF, Frye-Pierson J, et al. (1987). Factors influencing the survival of 451 transient ischemic attack patients. Stroke 18:552–557.PubMedCrossRefGoogle Scholar
  14. 14.
    Allen CMC (1984). Predicting the outcome of acute stroke: a prognostic score. J Neurol Neurosurg Psychiatry 47:475–480.PubMedCrossRefGoogle Scholar
  15. 15.
    Fullerton KJ, Mackenzie G, Stout RW (1988). Prognostic indices in stroke. Q J Med 250: 147–162.Google Scholar
  16. 16.
    Oxbury JM, Greenhall RCD, Grainger KMR (1975). Predicting the outcome of stroke: Acute stage after cerebral infarction. Br Med J 3:125–127.PubMedCrossRefGoogle Scholar
  17. 17.
    Barer DH, Ebrahim SB, Mitchell JRA (1988). The pragmatic approach to stroke trial design: Stroke register, pilot trial, assessment of neurological and functional outcome. Neuroepide-miology 7:1–12.CrossRefGoogle Scholar
  18. 18.
    Marshall J, Shaw DA (1960). Anticoagulant therapy in acute cerebrovascular accidents: a controlled trial. Lancet 1:955–998.Google Scholar
  19. 19.
    Jonas S (1988). Anticoagulant therapy in cerebrovascular disease: review and meta-analysis. Stroke 19:1043–1048.PubMedCrossRefGoogle Scholar
  20. 20.
    Spence JD, Donner A (1982). Problems in design of stroke treatment trials. Stroke 13:94–99.PubMedCrossRefGoogle Scholar
  21. 21.
    Capildeo R, Orgogozo JM (1988). Methodology of clinical trials in stroke. Part 1: analysis of previous clinical trials. In Capildeo R, Orgogozo JM (eds.) Methods in Clinical Trials in Neurology. Houdsmills, Basingtoke, Hampshire and London: M Stockton Press, pp. 137–151.Google Scholar
  22. 22.
    Fields WS, Lemak NA, Frankowski RF, et al. (1978). Controlled trial of aspirin in cerebral ischemia. Stroke 9:309–318.PubMedCrossRefGoogle Scholar
  23. 23.
    Canadian Cooperative Study Group (1978). An randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 299:53–59.CrossRefGoogle Scholar
  24. 24.
    Antiplatelet Trialists’ Collaboration (1988). Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br J Med 296:320–331.CrossRefGoogle Scholar
  25. 25.
    North American Symptomatic Carotid Endarterectomy Study Group (1987). Carotid endar-terectomy: three critical evaluations. Stroke 18:987–989.CrossRefGoogle Scholar
  26. 26.
    Freedman B (1988). Equipoise and the ethics of clinical research. N Engl J Med 317:141–145.CrossRefGoogle Scholar
  27. 27.
    Adams HP, Kassel NF, Mazuz H (1984). The patient with transient ischemic attacks — Is this the time for a new therapeutic approach? Stroke 15:371–375.PubMedCrossRefGoogle Scholar
  28. 28.
    Altmann J, Kornhuber AW, Kornhuber HH (1987). Stroke: cardiovascular risk factors and the quantitative effects of dietary treatment on them. Eur Neurol 26:90–99.PubMedCrossRefGoogle Scholar
  29. 29.
    Kendall BE, Pullicino P (1980). Intravascular contrast injection in ischaemic lesions. II. Effect on prognosis. Neuroradiology 19:241–243.PubMedGoogle Scholar
  30. 30.
    Jacobson PD, Rosenquist CJ (1988). The introduction of low-osmolar contrast agents in radiology. Medical, economic, legal and public policy issues. JAMA 260:1586–1592.PubMedCrossRefGoogle Scholar
  31. 31.
    Levy DE (1988). How transient are transient ischemic attacks? Neurology 38:674–677.PubMedGoogle Scholar
  32. 32.
    Werdelin L, Juhler M (1988). The course of transient ischemic attacks. Neurology 38:677–680.PubMedGoogle Scholar
  33. 33.
    Salgado E, Weistein M, Furlan AV, et al. (1986). Proton magnetic resonance imaging in ischemic cerebral vascular disease. Ann Neurol 20:502–507.PubMedCrossRefGoogle Scholar
  34. 34.
    Caplan LR (1988). TIAs: We need to return to the question, “What is wrong with Mr. Jones.” Neurology 38:791–793.PubMedGoogle Scholar
  35. 35.
    Hacke W, Zeumer H, Ferbert A, et al. (1988). Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 19:1216–1222.PubMedCrossRefGoogle Scholar
  36. 36.
    Scandinavian Stroke Study Group (1985). Multicenter trial of hemodilution in ischemic stroke — Background and study protocol. Stroke 16:885–890.CrossRefGoogle Scholar
  37. 37.
    Steiner TJ, Rose FC (1986). Towards a model stroke trial. The single-center Naftidrofuryl study. Neuroepidemiology 5:121–147.PubMedCrossRefGoogle Scholar
  38. 38.
    Gent M, Blakely JA, Hachinski V, et al. (1985) A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke 16:416–424.PubMedCrossRefGoogle Scholar
  39. 39.
    Gent M, Blakely JA, Easton JD, et al. (1988). The Canadian American Ticlopidine study (CATS) in thromboembolic stroke. Design, organisation, and baseline results. Stroke 19:1203–1210.PubMedCrossRefGoogle Scholar
  40. 40.
    Orgogozo JM, Capildeo R (1988). Methodology of clinical trials in stroke. Part II: Future trials — Recomendations. In Capildeo R, Orgogozo JM (eds.), Methods in Clinical Trials in Neurology. Houndmills, Basingtoke, Hampshire and London: M Stockton Press, pp. 207–221.Google Scholar
  41. 41.
    Italian Acute Stroke Study Group (1986). Italian Acute Stroke Study Hemodilution. An example of therapeutical protocol. In Battistini N, Fiorani O, Courbier R, et al. (eds.): Acute Brain Ischemia. Medical and Surgical Therapy. New York: Raven Press, p. 215–222.Google Scholar
  42. 42.
    Côte R, Hachinski VC, Shurvell BL, et al. (1986). The Canadian Neurological Scale: a preliminary study in acute stroke. Stroke 17:731–737.PubMedCrossRefGoogle Scholar
  43. 43.
    Orgogozo M, Capildeo R, Anagnostou CN (1983). Mise au point d’un score neurologique pour l’évaluation clinique des infarctus sylviens. Presse Med 12:3039–3043.PubMedGoogle Scholar
  44. 44.
    Adams RJ, Meador KJ, Sethi KD, et al. (1987). Graded neurologic scale for use in acute hemispheric stroke treatment protocols. Stroke 18:665–669.PubMedCrossRefGoogle Scholar
  45. 45.
    Abramson NS, Meisel A, Safar P (1986). Deferred consent: A new approach for resuscitation research. JAMA 255:2466–2471.PubMedCrossRefGoogle Scholar
  46. 46.
    Britton M, Roden A (1985). Progression of stroke after arrival at hospital. Stroke 16:629–632.PubMedCrossRefGoogle Scholar
  47. 47.
    Sterman AB, Furlan AJ, Pessin M, et al. (1987). Acute stroke therapy trials: an introduction to recurring design issues. Stroke 18:524–527.PubMedCrossRefGoogle Scholar
  48. 48.
    Côté R, Battista RN, Wolfson C, et al. (submitted). The Canadian neurological scale: validation and reliability assessment.Google Scholar
  49. 49.
    Prescott RJ, Garraway WM, Akhtar AJ (1982). Predicting functional outcome following acute stroke using a standard clinical examination. Stroke 13:641–647.PubMedCrossRefGoogle Scholar
  50. 50.
    Orgogozo JM, Dartigues FF (1986). Clinical trial in brain infarction. In Battistini N, Fiorani P, Courbier R, Plum F, Fieschi VC (eds), Acute Brain Ischemia: Medical and Surgical Therapy. New York: Raven Press, pp. 201–208.Google Scholar
  51. 51.
    Ebrahim S, Nouri F, Barer D (1985). Measuring disability after a stroke. J Epidemiol Community Health 39:86–89.PubMedCrossRefGoogle Scholar
  52. 52.
    Fletcher AE, Hunt BM, Bulpitt CJ (1987). Evaluation of quality of life in clinical trials of cardiovascular disease. J Chron Dis 40:557–566.PubMedCrossRefGoogle Scholar
  53. 53.
    Gelmers HJ, Gorter K, de Weerdt CJ, et al. (1988). A controlled trials of nimodipine in acute ischemic stroke. N Engl J Med 318:203–207.PubMedCrossRefGoogle Scholar
  54. 54.
    Donner A, Eliasziw M (1989). A critical review of methodology in recent stroke treatment trials. Presented at the Symposium on Clinical Trial Methodology in Stroke, Priory of Corsendonk, Belgium.Google Scholar
  55. 55.
    Vornov JJ, Levey A (1988). Nimodipine in acute ischemic stroke (letter to the editor). N Engl J Med 319:250.Google Scholar
  56. 56.
    Gelmers JH, Gorter K, de Weerdt CJ, et al. (1988). Nimodipine in acute ischemic stroke (letter to the editor). N Engl J Med 319:250.Google Scholar
  57. 57.
    Koudstaal PJ, Stibbe J, Vermeulen M. (1988). Fatal ischaemic brain oedema after early thrombolysis with tissue plasminogen activator in acute stroke. Br Med J 297:1571–1573.CrossRefGoogle Scholar
  58. 58.
    Dombovy ML, Sandok BA, Basford JR (1986). Rehabilitation for stroke: A review. Stroke 17:363–369.PubMedCrossRefGoogle Scholar
  59. 59.
    Smith ME, Garraway WM, Smith DK, et al. (1982). Therapy impact on functional outcome in a controlled trial of stroke rehabilitation. Arch Phys Med Rehabil 64:21–24.Google Scholar
  60. 60.
    Strand T, Asplund K, Eriksson S, et al. (1985). A non-intensive stroke unit reduces functional disability and the need for long term hospitalization. Stroke 16:29–34.PubMedCrossRefGoogle Scholar
  61. 61.
    Wade DT, Skilbeck CE, Langton Hewer R (1983). Predicting Barthel ADL score at 6 months after an acute stroke. Arch Phys Med Rehabil 64:24–28.PubMedGoogle Scholar
  62. 62.
    Osberg JS, Dejong G, Haley SM, et al. (1988). Predicting long-term outcome among post-rehabilitation stroke patients. Am J Phys Med Rehabil 2:94–103.CrossRefGoogle Scholar
  63. 63.
    Garraway WM, Akhtar AJ, Smith DL, et al. (1981). The triage of stroke rehabilitation. J Epidemiol Community Health 35:39–44.PubMedCrossRefGoogle Scholar
  64. 64.
    Reding MJ, Potes E (1988). Rehabilitation outcome following initial unilateral hemispheric stroke. Life-table analysis approach. Stroke 19:1354–1358.PubMedCrossRefGoogle Scholar
  65. 65.
    Novack TA, Satterfield WT, Connor M (1984). Stroke onset and rehabilitation: time lag as a factor in treatment outcome. Arch Phys Med Rehabil 65:316–319.PubMedGoogle Scholar
  66. 66.
    Seale C, Davies P (1987). Outcome measurement in stroke rehabilitation research. Int Disabil Studies 9:155–160.CrossRefGoogle Scholar
  67. 67.
    Wade DT, Collin C (1988). The Barthel ADL index: a standard measure of physical disability? Int Disabil Stud 10:64–67.PubMedCrossRefGoogle Scholar
  68. 68.
    Bamford J, Sandercock P, Dennis M, et al. (1988). A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981–1986. 1. Methodology, demography and incident cases of first-ever stroke. J Neurol Neurosurg Psychiatry 51:1373–1380.PubMedCrossRefGoogle Scholar
  69. 69.
    Grotta JC, Lemak NA, Gary H, et al. (1985). Does platelet antiaggregant therapy lessen the severity of stroke? Neurology 35:632–636.PubMedGoogle Scholar
  70. 70.
    Warlow CP (1988). Trials of secondary prevention after transient ischaemic attacks. Part II: Towards better clinical trials. In Capildeo R, Orgogozo J-M (eds.), Methods in Clinical Trials in Neurology. Houndmills, Basingstoke, Hampshire and London: M Stockton Press, pp. 153–173.Google Scholar
  71. 71.
    Taylor DW, Sackett DL, Haynes B (1984). Sample size for randomized trials in stroke prevention. How many patients do we need? Stroke 15:968–971.PubMedCrossRefGoogle Scholar
  72. 72.
    Perry HM, Smith WM, McDonald RH (1989). Morbidity and mortality in the systolic hypertension in the elderly program (SHEP) pilot study. Stroke 20:4–13.PubMedCrossRefGoogle Scholar
  73. 73.
    Relman AS (1987). The extracranial-intracranial arterial bypass study: What have we learned? N Engl J Med 316:809–810.PubMedCrossRefGoogle Scholar
  74. 74.
    Barnett HJM, Sackett D, Taylor DW, et al. (1987). Are the results of the extracranial-intracranial bypass trial generalizable? N Engl J Med 316:820–824.PubMedCrossRefGoogle Scholar
  75. 75.
    Lancet (1989). In press.Google Scholar
  76. 76.
    Haas W (1988). 1988 Canadian Stroke Society Lecturer (program). Can J Neurol Sci 15:181.Google Scholar
  77. 77.
    Gent M. (1988). 1988 Canadian Stroke Society Lecturer (program). CanJ Neurol Sci 15:181.Google Scholar
  78. 78.
    Warlow C (1984). Carotid endarterectomy: Does it work? Stroke 15:1068–1076.PubMedCrossRefGoogle Scholar
  79. 79.
    Committee on Health Care Issues, American Neurological Association (1987). Does carotid endarterectomy decrease stroke and death in patients with transient ischemic attacks? Ann Neurol 22:72–76.CrossRefGoogle Scholar
  80. 80.
    Winslow CM, Solomon DH, Chassin MR, et al. (1988). The appropriateness of carotid endarterectomy. N Engl J Med 318:721–727.PubMedCrossRefGoogle Scholar
  81. 81.
    Whisnant JP, Wiebers DO (1987). Clinical epidemiology of transient cerebral ischemic attacks (TIA) in the anterior and posterior cerebral circulation. In Sundt TM Jr (ed.), Occlusive Cerebrovascular Disease: Diagnosis and Surgical Management. Philadelphia: Saunders, pp. 60–65.Google Scholar
  82. 82.
    The European Stroke Prevention Study Group (1987). The European stroke prevention study (EPSP): principal endpoints. Lancet 1:406–415.Google Scholar
  83. 83.
    Laupacis A, Sackett DL, Roberts RS (1988). An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318:1728–1733.PubMedCrossRefGoogle Scholar
  84. 84.
    Thacker SB (1988). Meta-analysis. A quantitative approach to research integration. JAMA 259:1685–1689.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Michel A. Beaudry
  • Vladimir C. Hachinski

There are no affiliations available

Personalised recommendations